IL6 and rheumatoid arthritis: Considering the pro-inflammatory role of IL-6, the strong positive correlation between IL-6 concentrations and mortality, and the adverse event profile of tocilizumab in thousands of rheumatoid arthritis patients likely treated multiple times, single administration of tocilizumab during severe MCA events is justified [28–31].